

MOU for Cannabis Oils from Canadian Producer

Impression Healthcare Limited ('IHL') is pleased to announce that it has executed a Memorandum of Understanding ('MoU') with an established and reputable Canadian producer of cannabis oils (the 'Manufacturer').

The MoU contemplates:

- the commencement of a wholesale cannabis oil supply agreement
- the guaranteed supply of formulated, filled and labelled bottles for distribution by IHL
- the provision of soft gel capsules relevant to the manufacture of Dronabinol in support of IHL's license agreement with Resolution Chemicals announced on the 04th of December 2018.

Packaged cannabis oil products will be provided to patients under the Special Access Scheme and the Authorised Prescriber Scheme for a wide range of indications relevant to multiple medical fields. Having cannabis oils available for distribution to doctors and patients from a major reputable supplier will facilitate the development of IHL's doctor outreach program, even prior to the receipt of the medicinal cannabis license.

The Manufacturer specialises in extraction and purification of cannabis concentrates and follows international standards for quality. The Manufacturer works with established cultivation partners to produce pharmaceutical-grade cannabis oils. The name of the Manufacturer is currently withheld as commercial in confidence and the two parties will endeavour to reach a formal supply arrangement in the short term.

Impression Healthcare CEO, Mr Joel Latham said; "This is another exceptional opportunity for Impression to distribute high-quality cannabinoid medicines into the Australian market with a proven and experienced manufacturing partner.

Today's announcement is a natural follow-on to the submission of our medicinal cannabis license last week and will enable us to distribute more product, relevant to more medical practitioners after the receipt of our license.

Having product security over a range of pharmaceutical-grade cannabis oils from a proficient supplier will be important to the ongoing development of our doctor and patient outreach programs".

ENDS



Date: 19 December 2018
ASX Announcement (ASX: IHL)

About Impression Healthcare Limited (ASX: IHL)

Impression Healthcare Limited is Australia's largest home dental impression company and is disrupting the dental devices market by providing consumers with an in-home method to consume laboratory-grade and personalised dental healthcare products at significantly lower prices than those offered by the traditional dental industry. Impression has significantly grown its distribution footprint and increased its revenues by 359% in the 2018 Financial Year. With its own dental laboratory in Victoria, Australia Impression offers best in class teeth protection and helps its customers combat bruxism, snoring, mild to moderate sleep apnoea and teeth discolouration with custom-fitted oral devices.

Impression is broadening its commitment to disruption in the healthcare sector by exploring opportunities in medicinal cannabis distribution and development, underpinned by collaboration and licensing agreements with leading US Cannabinoid therapeutics Company, AXIM Biotechnologies Inc. AXIM is focused on research, development and production of oral health, pharmaceutical, nutraceutical and cosmetic products incorporating cannabinoids for a wide range of indications. Impression will leverage its oral health marketing activities to explore opportunities distribute a range of AXIM's over the counter and therapeutic products as public opinion of cannabinoid-based therapeutics steadily improves.

Investors: investors@impression.healthcare

Website: www.impression.healthcare